Safety and immunogenicity of an attenuated Chinese pseudorabies variant by dual deletion of TK&gE genes

BMC Veterinary Research

Table 3 Group division and results of antibodies, clinical signs and lung lesions in efficacy test

Groups			A	B	C	D	E	F
Virus tested			PRV^ΔTK&gE-AH02			Bartha K61	/	/
Dosage (TCID₅₀)			10³	10⁴	10⁵	10⁵	/	/
Inoculation route			Intramuscularly
ELISA antibodies against PRV gB or gE	B.V.	gB+	0^a/4^b	0/4	0/4	0/4	0/4	0/4
	B.V.	gE+	0/4	0/4	0/4	0/4	0/4	0/4
	7d P.V.	gB+	4/4	4/4	4/4	4/4	0/4	0/4
	7d P.V.	gE+	0/4	0/4	0/4	0/4	0/4	0/4
	14 d P.C.	gB+	4/4	4/4	4/4	4/4	0/4	0/4
	14 d P.C.	gE+	4/4	4/4	4/4	4/4	1/1	0/4
Clinical signs P.V.			0/4	0/4	0/4	0/4	0/4	0/4
Fever frequency (≥40.5 °C) P.V.			0/4	0/4	0/4	0/4	0/4	0/4
Virus shedding P.V.			0/4	0/4	0/4	0/4	/	/
Fever frequency (≥40.5 °C) P.C.			0/4	0/4	0/4	4/4	4/4	0/4
Clinical signs P.C.	Morbidity		0/4	0/4	0/4	0/4	4/4	0/4
	Duration (days)		/	/	/	/	4~ 9	/
	Mortality		0/4	0/4	0/4	0/4	3/4	0/4
Virus shedding P.C.	Frequency		0/4	0/4	0/4	4/4	4/4	0/4
Virus shedding P.C.	Duration (days)		/	/	/	3~ 5	2~ 9	/
Lung lesions			0/4	0/4	0/4	2/4	4/4	0/4

B.V. means before vaccination, P.V. means post vaccination, P.C. means post challenge, gB+ means antibodies against PRV gB positive, gE+ means antibodies against PRV gE positive, “^a” indicates the number of piglets positive; “^b” indicates the number of piglets in the group

ISSN: 1746-6148